Smith Asset Management Group LP cut its position in shares of Chemed Corp. (NYSE:CHE) by 9.5% during the second quarter, Holdings Channel reports. The firm owned 21,695 shares of the company’s stock after selling 2,284 shares during the period. Smith Asset Management Group LP’s holdings in Chemed Corp. were worth $4,437,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of CHE. BlackRock Inc. boosted its stake in Chemed Corp. by 145,760.9% in the first quarter. BlackRock Inc. now owns 1,955,994 shares of the company’s stock worth $357,341,000 after buying an additional 1,954,653 shares during the period. Vanguard Group Inc. boosted its stake in Chemed Corp. by 7.5% in the first quarter. Vanguard Group Inc. now owns 1,795,773 shares of the company’s stock worth $328,070,000 after buying an additional 125,018 shares during the period. Neuberger Berman Group LLC boosted its stake in Chemed Corp. by 2.2% in the first quarter. Neuberger Berman Group LLC now owns 1,060,403 shares of the company’s stock worth $193,725,000 after buying an additional 23,306 shares during the period. Acadian Asset Management LLC boosted its stake in Chemed Corp. by 1.3% in the second quarter. Acadian Asset Management LLC now owns 579,170 shares of the company’s stock worth $118,454,000 after buying an additional 7,636 shares during the period. Finally, Van Berkom & Associates Inc. boosted its stake in Chemed Corp. by 0.5% in the first quarter. Van Berkom & Associates Inc. now owns 467,536 shares of the company’s stock worth $85,414,000 after buying an additional 2,260 shares during the period. Institutional investors and hedge funds own 98.33% of the company’s stock.

Chemed Corp. (NYSE:CHE) opened at 191.88 on Friday. Chemed Corp. has a 52-week low of $130.05 and a 52-week high of $216.01. The firm’s 50-day moving average price is $201.50 and its 200 day moving average price is $191.93. The company has a market cap of $3.07 billion, a PE ratio of 47.60 and a beta of 1.14.

Chemed Corp. (NYSE:CHE) last issued its earnings results on Tuesday, July 25th. The company reported $2.15 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.89 by $0.26. The firm had revenue of $415.06 million for the quarter, compared to analyst estimates of $407.56 million. Chemed Corp. had a return on equity of 26.18% and a net margin of 4.16%. The business’s revenue was up 6.3% on a year-over-year basis. During the same period in the previous year, the company posted $1.80 earnings per share. On average, equities analysts predict that Chemed Corp. will post $8.20 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, September 1st. Shareholders of record on Monday, August 14th will be paid a $0.28 dividend. The ex-dividend date is Thursday, August 10th. This is a positive change from Chemed Corp.’s previous quarterly dividend of $0.26. This represents a $1.12 annualized dividend and a dividend yield of 0.58%. Chemed Corp.’s payout ratio is presently 28.07%.

TRADEMARK VIOLATION WARNING: “Chemed Corp. (CHE) Shares Sold by Smith Asset Management Group LP” was posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this story on another domain, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this story can be read at https://theolympiareport.com/2017/08/12/chemed-corp-che-shares-sold-by-smith-asset-management-group-lp.html.

CHE has been the topic of a number of research analyst reports. TheStreet cut Chemed Corp. from a “b+” rating to a “c+” rating in a research note on Tuesday, July 25th. Zacks Investment Research cut Chemed Corp. from a “buy” rating to a “hold” rating in a research note on Tuesday, May 2nd. BidaskClub cut Chemed Corp. from a “buy” rating to a “hold” rating in a research note on Wednesday, August 2nd. Royal Bank Of Canada restated a “hold” rating and issued a $209.00 price target on shares of Chemed Corp. in a research note on Monday, July 31st. Finally, Oppenheimer Holdings, Inc. increased their price target on Chemed Corp. from $200.00 to $220.00 and gave the company an “outperform” rating in a research note on Thursday, July 27th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $218.33.

In other news, Director George J. Walsh III bought 1,000 shares of the stock in a transaction on Monday, June 26th. The shares were purchased at an average cost of $204.56 per share, for a total transaction of $204,560.00. Following the completion of the purchase, the director now directly owns 7,908 shares in the company, valued at approximately $1,617,660.48. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Kevin J. Mcnamara sold 15,000 shares of the business’s stock in a transaction on Friday, July 28th. The shares were sold at an average price of $201.16, for a total value of $3,017,400.00. Following the completion of the sale, the insider now owns 173,801 shares in the company, valued at $34,961,809.16. The disclosure for this sale can be found here. Insiders own 5.32% of the company’s stock.

About Chemed Corp.

Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.

Want to see what other hedge funds are holding CHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemed Corp. (NYSE:CHE).

Institutional Ownership by Quarter for Chemed Corp. (NYSE:CHE)

Receive News & Ratings for Chemed Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed Corp. and related companies with Analyst Ratings Network's FREE daily email newsletter.